info@seagull-health.com
SeagullHealth
语言:
search

Encorafenib(BRAFTOVI)

Names
BRAFTOVI,Encorafenib康奈非尼,恩考芬尼
Indicatons
For the treatment of melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
Price:
Manufacturer:
‌Pierre Fabre
Dosage form:
CAPSULE
Validity period:
24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

BRAFTOVI(Encorafenib) Instructions:Uses,Dosage, Side Effects

TEMBEXA® (brincidofovir) is an antiviral medication developed for the treatment of human smallpox disease, a potentially fatal infection caused by the variola virus. It is a nucleotide analog that inhibits viral DNA replication, helping to reduce the severity and progression of the disease. 

TEMBEXA® is primarily indicated for adults and children (including neonates), and while the drug has been shown to be effective in animal models, its human efficacy has not been definitively proven due to ethical constraints in conducting smallpox challenge studies. It is available as both tablets and oral suspension for patients who have difficulty swallowing pills.

Despite its potential benefits in treating smallpox, TEMBEXA® requires careful monitoring due to its potential to cause liver toxicity and gastrointestinal disturbances. It should be used with caution in individuals of childbearing potential due to risks of embryo-fetal toxicity and male infertility, as shown in animal studies. Given its significant side effect profile, TEMBEXA® is primarily used in the context of emergency preparedness in the event of a smallpox outbreak or bioterrorism attack.

Generic name
Encorafenib(BRAFTOVI)
English name
Encorafenib
Alternative Names
BRAFTOVI,Encorafenib康奈非尼,恩考芬尼
Drug prices
Indications

BRAFTOVI is indicated for the treatment of adult patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.

Therapeutic Target
BRAFTOVI targets BRAF, a serine/threonine kinase involved in the RAS/RAF/MEK/ERK signaling pathway.
Active Ingredients
Encorafenib is the active ingredient in BRAFTOVI. It is a potent and selective inhibitor of the mutant BRAF kinase.
Dosage Form
CAPSULE
Specifications
75mg*42capsules/box
Dosage and Administration

The recommended dosage of BRAFTOVI is 450 mg taken orally once daily. It is used in combination with binimetinib, which should be administered at 24 mg twice daily.

    Recommended articles
    Related articles
    How to Use Encorafenib (Braftovi)
    Encorafenib (Braftovi) is a kinase inhibitor that was first approved in the United States in 2018 for the treatment of advanced malignant tumors harboring specific BRAF gene mutations.How to Use Encor...
    Indications of Encorafenib (Braftovi)
    Encorafenib (Braftovi) is an oral kinase inhibitor that first received approval for marketing from the U.S. Food and Drug Administration (FDA) in 2018. Specifically designed to treat malignant tumors ...
    How to Purchase Encorafenib (Braftovi)
    Encorafenib (Braftovi) is an important kinase inhibitor drug used for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer with...
    What are the side effects of Encorafenib?
    Encorafenib IS AN ORAL SMALL MOLECULE BRAF INHIBITOR DEVELOPED BY ARRAY BIOPHARMA IN THE UNITED STATES. In the Chinese market, the French company Pierre Fabre has obtained an exclusive commercializati...
    Adverse effects of Encorafenib(BRAFTOVI)
    Encorafenib (BRAFTOVI) is a therapeutic drug that targets BRAF gene mutations, which may cause a series of adverse reactions while bringing significant efficacy. Adverse effects of Encorafenib (BRAFTO...
    What are the side effects of Encorafenib?
    Encorafenib in combination with bimetinib is indicated for the treatment of adult patients with metastatic NSCLC detected by an FDA-approved test with a BRAF V600E mutation. The approval builds on pos...
    New Drugs
    Infigratinib(Truseltiq)
    Infigratinib(Truseltiq)
    Treatment of previously treated, unresectable locally advanced or metastatic...
    Opicapone(Ongentys)
    Opicapone(Ongentys)
    Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
    Deflazacort(Emflaza)
    Deflazacort(Emflaza)
    Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
    Faricimab-svoa(Vabysmo)
    Faricimab-svoa(Vabysmo)
    Treatment of neovascular age-related macular degeneration, diabetic macular...
    Counselling Service
    Global Drug Search
    Clinical Research Recruitment
    Overseas Medical Treatment
    Remote Consultations
    Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
    Submit
    Business
    • Core products
    • Antitumor drugs
    • General drug
    • Antiviral drugs
    • Biological agents
    Contact Us 
    • mailbox:info@lucius.la
    Welcome to consult
    ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved